je.st
news
Home
› VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
2013-06-24 09:13:00| drugdiscoveryonline News Articles
VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), recently announced a licensing deal for a novel antibody against an undisclosed hematological cancer target
Tags: deal
target
candidate
licensing
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||